DJIA 17,151.63 120.49 0.71%
NASDAQ 4,550.78 31.88 0.71%
S&P 500 2,001.17 17.04 0.86%
market minute promo

Dendreon Corp (NASDAQ: DNDN)



company name or ticker
Company Photos
(Click to zoom)

Is Pfizer Putting the Car-T Before the Horse?

Pfizer has moved to establish a good preclinical presence in a promising emerging cancer therapy class

3 Terrific Reasons To Buy Dendreon

Dendreon: An Update On The Debt Situation

Is Gene Therapy Medicine's Next Big Thing?

Bluebird Bio (BLUE) is advancing gene therapies through clinic using technology that Celgene (CELG) thinks could someday be used to treat cancer.

Dendreon CEO To Shorts: Bombs Away!

Dendreon's CEO Departs at Critical Juncture - Analyst Blog

Dendreon's CEO Exits: Is this the Beginning of the End?

Dendreon CEO John Johnson announced yesterday that he is stepping down for "personal reasons." His departure comes ahead of a large company debt payment. Could Dendreon be on the precipice of bankruptcy?

Cantor Weighs In On Dendreon Leadership Change

Morning Market Losers

Tuesday’s Top Biotech Stories: Achillion, Receptos, and Dendreon

Achillion, Receptos, and Dendreon could all make waves in biotech headlines this Tuesday morning.
See More Articles...